European Biochemical Engineering Society Sets Vision - - BioPharm International

ADVERTISEMENT

European Biochemical Engineering Society Sets Vision


The European Society of Biochemical Engineering Sciences (ESBES), which was established in April 2013 and is the successor body to the ESBES section of the European Federation of Biotechnology, met for the first time in June to set out a vision and mission, the society announced in a press release. 
The membership organization has been established to bring together national chemical and biochemical engineering societies from across Europe, especially in the fields of downstream processing; bioreactor performance; biocatalysis; bioenergy systems; and modeling, monitoring, measurement, and control. 



The mission of ESBES is to promote cooperation between industry and academia for the advancement of biochemical engineering sciences. 
“Our vision is to help solve major societal challenges associated with population changes and limited resources and to improve the quality of life. The biochemical engineering sciences are key to addressing issues linked to our growing and aging population and to developing a more sustainable way of life,” ESBES’ president, Guilherme Ferreira, explained in the press release. “We believe that biochemical engineering sciences are pivotal to driving technology development for European industry competitiveness. We want to help translate knowledge into processes and products and advance education for the new bio-economy era. For bioengineering science to achieve its full potential we need to ensure that Europe’s regulatory framework and research and development policies support this exciting new industry.”

ESBES receives secretariat support from the Institution of Chemical Engineers (IChemE); the Gesellschaft für Chemische Technik und Biotechnologie e.V. (DECHEMA), Germany; and Société Française de Génie de Procédés (SFGP), France.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines

Click here